Banque Cantonale Vaudoise Boosts Stock Position in IDEXX Laboratories, Inc. $IDXX

Banque Cantonale Vaudoise grew its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 36.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,966 shares of the company’s stock after buying an additional 1,603 shares during the period. Banque Cantonale Vaudoise’s holdings in IDEXX Laboratories were worth $4,037,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the stock. Beacon Investment Advisory Services Inc. increased its stake in IDEXX Laboratories by 11.9% in the 4th quarter. Beacon Investment Advisory Services Inc. now owns 62,951 shares of the company’s stock worth $42,588,000 after acquiring an additional 6,710 shares during the last quarter. Nordea Investment Management AB increased its stake in IDEXX Laboratories by 114.1% in the 4th quarter. Nordea Investment Management AB now owns 16,597 shares of the company’s stock worth $11,283,000 after acquiring an additional 8,845 shares during the last quarter. New York State Common Retirement Fund increased its stake in IDEXX Laboratories by 6.8% in the 3rd quarter. New York State Common Retirement Fund now owns 60,225 shares of the company’s stock worth $38,477,000 after acquiring an additional 3,820 shares during the last quarter. Mediolanum International Funds Ltd increased its stake in IDEXX Laboratories by 14.5% in the 3rd quarter. Mediolanum International Funds Ltd now owns 38,761 shares of the company’s stock worth $24,441,000 after acquiring an additional 4,909 shares during the last quarter. Finally, Procyon Advisors LLC bought a new stake in IDEXX Laboratories in the 4th quarter worth approximately $1,966,000. 87.84% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 1,758 shares of the company’s stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $634.57, for a total value of $1,115,574.06. Following the completion of the sale, the executive vice president directly owned 18,141 shares in the company, valued at approximately $11,511,734.37. This represents a 8.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jonathan Jay Mazelsky sold 23,326 shares of the company’s stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $657.55, for a total value of $15,338,011.30. Following the completion of the sale, the chief executive officer owned 83,606 shares of the company’s stock, valued at $54,975,125.30. This represents a 21.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 27,777 shares of company stock valued at $18,235,113 over the last quarter. Company insiders own 0.79% of the company’s stock.

Analyst Upgrades and Downgrades

IDXX has been the topic of a number of research reports. BTIG Research reduced their price objective on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a research note on Tuesday, February 3rd. Stifel Nicolaus reduced their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research note on Tuesday, March 31st. UBS Group reduced their price objective on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 28th. Piper Sandler reduced their price objective on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research note on Monday, February 9th. Finally, Citigroup started coverage on IDEXX Laboratories in a research report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 target price on the stock. Seven equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $751.00.

IDEXX Laboratories Price Performance

IDXX opened at $553.58 on Thursday. The business has a fifty day moving average of $568.24 and a 200 day moving average of $643.82. IDEXX Laboratories, Inc. has a 52-week low of $496.61 and a 52-week high of $769.98. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. The stock has a market cap of $43.67 billion, a P/E ratio of 40.76, a PEG ratio of 3.17 and a beta of 1.58.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.12 billion. During the same quarter in the previous year, the business earned $2.91 EPS. IDEXX Laboratories’s revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.